GTL 001

Drug Profile

GTL 001

Alternative Names: CyAa-HPV-16E7 CyaA-HPV-18E7 vaccine; GTL001; HPV 16E7 HPV 18E7 protein vaccine; HPV 16E7-HPV 18E7; ProCervix

Latest Information Update: 05 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GENTICEL
  • Developer GenKyoTex; GENTICEL
  • Class Papillomavirus vaccines; Protein-vaccines; Recombinant proteins; Synthetic vaccines
  • Mechanism of Action CD4-positive T lymphocyte stimulants; CD8 positive T lymphocyte stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Oropharyngeal cancer
  • Discontinued Anal cancer; Cancer; Cervical cancer; Human papillomavirus infections

Most Recent Events

  • 13 Dec 2016 Final efficacy and adverse events data from the phase II RHEIA-VAC trial in Cervical cancer released by Genticel
  • 01 Dec 2016 Genticel terminates a phase I trial in Human papillomavirus infections in USA due to lack of efficacy in European Phase II study (Parenteral) (NCT02689726)
  • 01 Oct 2016 Genticel completes the RHEIA-VAC trial in Cervical cancer (Prevention)/Human papillomavirus infections in United Kingdom, Belgium, Finland, France, Germany, Netherlands and Spain (NCT01957878)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top